In Sight

Regular price €34.99
Title
Quantity:
In stock with our UK publisher. 14-28 days
Delivery/Collection within 10-20 working days
14 days return policy Shipping & Delivery
A01=Julia Levy
Author_Julia Levy
biography
biotechnology
careers
Category=DNBB1
Category=KJD
Category=KJF
Category=KJV
Category=MBD
Category=MBF
Category=MBGT
Category=MBNH9
Category=MK
Category=MQU
commercialisation of science
eq_bestseller
eq_biography-true-stories
eq_business-finance-law
eq_isMigrated=1
eq_nobargain
eq_non-fiction
IPO
macular degeneration
memoir
photodynamic
QLT
STEM
therapy
Visudyne
women in business
women in science

Product details

  • ISBN 9781487508319
  • Weight: 600g
  • Dimensions: 161 x 235mm
  • Publication Date: 23 Oct 2020
  • Publisher: University of Toronto Press
  • Publication City/Country: CA
  • Product Form: Hardback
Secure checkout Fast Shipping Easy returns

In Sight is a memoir about how a love of science and discovery drove Julia Levy, a celebrated scholar and biotech CEO, to work her way through gender bias in order to achieve academic and professional recognition. Her story traces the unconventional invention of a breakthrough drug treatment from its development from laboratory research to its application as a medical treatment for vision loss.

Told from a female perspective, In Sight is a unique and personal story covering Levy’s early years as a refugee, her university training in the UK, and her appointment as professor at the University of British Columbia. Years spent as an academic led the author to unexpected exposure to the biotechnology industry and a chance meeting with colleagues that led to the formation of a lucrative biotechnology company, known today as QLT Inc. The bulk of the book covers the years spent building the company, and Levy’s surprising transition from chief scientific officer to CEO. In Sight is an honest description of the trials of drug development, the tensions inherent in the commercialization of health innovations, and the truly remarkable hurdles faced by women in the scientific community.

Julia Levy has been a leader in the fields of science, education, and business. She served first as chief scientific officer and later as chief executive officer of QLT. During her tenure as CEO the company obtained regulatory approval for its macular degeneration treatment that resulted in the financial success of QLT Inc. She is an officer of the Order of Canada and has received a number of honorary degrees.

More from this author